Terms: = Ovarian cancer AND PRRX1, ENSG00000116132, 5396
5 results:
1. Activation of COL11A1 by prrx1 promotes tumor progression and radioresistance in ovarian cancer.
Zhu M; Ye C; Wang J; Yang G; Ying X
Int J Radiat Biol; 2021; 97(7):958-967. PubMed ID: 33970764
[TBL] [Abstract] [Full Text] [Related]
2. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
Zuo L; Li X; Tan Y; Zhu H; Xiao M
J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
[TBL] [Abstract] [Full Text] [Related]
3. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Wang X; Liu H; Maimaitiaili A; Zhao G; Li S; Lv Z; Wu D; Shi A; Guan X; Jia H; Li M; Song D; Kang L; Han B; Fu T; Yang M; Zhu Z; Du Y; Song Y; Hong J; Fan Z
Mol Genet Genomic Med; 2019 Jun; 7(6):e677. PubMed ID: 30968603
[TBL] [Abstract] [Full Text] [Related]
4. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract] [Full Text] [Related]
5. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Elstrodt F; Hollestelle A; Nagel JH; Gorin M; Wasielewski M; van den Ouweland A; Merajver SD; Ethier SP; Schutte M
Cancer Res; 2006 Jan; 66(1):41-5. PubMed ID: 16397213
[TBL] [Abstract] [Full Text] [Related]
